Giredestrant plus Everolimus in Advanced Breast Cancer.

Giredestrant combined with everolimus significantly extends progression-free survival in ER-positive, HER2-negative advanced breast cancer, especially in ESR1-mutated tumors, with a median of 10 months versus 5.5 months.

• Why it matters: Overcoming endocrine-therapy resistance remains a critical challenge in advanced breast cancer treatment, particularly for patients with ESR1 mutations who have progressed after prior therapies.
• What they did: A phase 3 trial enrolled 373 patients with advanced breast cancer post-CDK4/6 inhibitor therapy, comparing giredestrant plus everolimus to standard endocrine therapy plus everolimus, assessing progression-free survival.
• The result: The combination therapy improved median progression-free survival across all patients and notably in those with ESR1 mutations, with similar adverse event rates, supporting its potential as a new treatment option.